Compare HP & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HP | CRNX |
|---|---|---|
| Founded | 1920 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | HP | CRNX |
|---|---|---|
| Price | $30.92 | $38.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $34.17 | ★ $76.75 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,746,013,000.00 | $1,039,000.00 |
| Revenue This Year | $9.50 | $720.10 |
| Revenue Next Year | $3.34 | $184.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 35.89 | N/A |
| 52 Week Low | $15.17 | $25.83 |
| 52 Week High | $41.82 | $57.99 |
| Indicator | HP | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 30.16 | 62.31 |
| Support Level | $25.05 | $38.08 |
| Resistance Level | $36.65 | $44.89 |
| Average True Range (ATR) | 1.42 | 1.65 |
| MACD | -0.51 | 0.48 |
| Stochastic Oscillator | 1.09 | 88.70 |
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.